Carroll Investors’s Insight Molecular Diagnostics IMDX Stock Holding History

Carroll Investors’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-15	Closed	–	–	124
2022 Q1	$0	Hold	15	–	–	﹤0.01%	200
2021 Q4	$0	Buy	+15	New	+$863	﹤0.01%	197

Other funds holding IMDX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

Carroll Investors's IMDX Position: Q2 2022 in Review

Carroll Investors sold out of Insight Molecular Diagnostics (IMDX) in Q2 2022, closing a stake of 15 shares.

Carroll Investors first reported a position in IMDX in Q4 2021 and held it in 2 quarters. The position peaked at $0 in Q1 2022. 75 funds tracked by Wall St. Rank hold IMDX as of Q2 2022.

Carroll Investors reported no remaining Insight Molecular Diagnostics position as of Q2 2022 after selling out during the quarter.
Carroll Investors sold 15 Insight Molecular Diagnostics shares in Q2 2022.
Carroll Investors first reported a position in Insight Molecular Diagnostics in Q4 2021 and held it in 2 quarters.
Carroll Investors's Insight Molecular Diagnostics position peaked at $0 in Q1 2022.
75 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2022.

Based on Carroll Investors's 13F filing for Q2 2022, filed 26 Jul 2022.